3 recruiting, 1 completed, 1 terminated. 4 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 4 | Recruiting 3, Terminated 1 |
Follow Alentis Therapeutics AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors ALE.P03 - Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Alentis Therapeutics AG | 180 | 2025-08-26 | 2026-07-02 |
| A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors ALE.P02 - Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Alentis Therapeutics AG | 170 | 2024-12-16 | 2026-06-29 |
| Study of ALE.C04 in Patients With Head and Neck Cancer ALE.C04, Pembrolizumab - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Alentis Therapeutics AG | 21 | 2023-10-30 | 2025-02-17 |
| Rescue of Nephrons With ALE.F02 (RENAL-F02) ALE.F02, Rituximab, GlucoCorticoid - Glomerulonephritis Rapidly Progressive | Phase 2 | Recruiting | Alentis Therapeutics AG | 80 | 2023-09-07 | 2026-08-14 |
| A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis ALE.F02, Placebo - Advanced Liver Fibrosis, Liver Cirrhosis | Phase 1 | Completed | Alentis Therapeutics AG | 41 | 2023-04-01 | 2024-12-03 |
Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1) · Liver Cirrhosis (1)
Cyclophosphamide (1) · Glucocorticoids (1) · Immunosuppressive Agents (1) · Rituximab (1) · pembrolizumab (1)
France (4) · Italy (4) · Spain (4) · United States (4) · Hong Kong (3) · Singapore (3) · Germany (2) · Switzerland (2) · Taiwan (2) · Canada (1) · Czechia (1) · Denmark (1) · Netherlands (1) · Romania (1) · Slovakia (1)
2025 (1)